Personalized Medicine Market Size Worth USD 1,397.63 Bn by 2035 Rising Use of Genomics Enables More Precise, Patient-specific Treatments

BioSpace· June 17, 2026

Personalized Medicine Market Size Worth USD 1,397.63 Bn by 2035 Rising Use of Genomics Enables More Precise, Patient-specific Treatments BioSpace

Read the full story at BioSpace

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to BioSpace.

More in Genomics & Precision Medicine

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Illumina has partnered with Tempus to advance precision medicine through the integration of genomic AI innovation and sequencing technologies. This collaboration focuses on delivering scalable solutions for analyzing genetic variation and function, aiming to support advancements in life science research and molecular diagnostics. By combining their expertise, the companies seek to enable complex genomic studies and streamline sequencing workflows for global customers.

June 21, 2026

How AI in Genomics is Transforming Healthcare and Research

The integration of artificial intelligence into genomics is driving a significant shift in healthcare and research by automating the analysis of complex genetic datasets. This technological evolution is projected to expand the AI genomics market from USD 484.1 million in 2022 to USD 12.5 billion by 2032, reflecting a growth rate of 39.2%. By leveraging machine learning and deep learning, the sector is achieving faster, more precise, and cost-effective discoveries in areas such as gene editing and clinical diagnostics.

June 20, 2026

Metropolis Healthcare launches Centre of Genomics

Metropolis Healthcare has announced the launch of its dedicated Centre of Genomics, signaling a strategic expansion into the specialized field of genetic diagnostics. This initiative is positioned to address the rising demand for precision medicine tools that utilize genomic sequencing to inform clinical decision-making. By establishing this center, Metropolis aims to enhance the accessibility of advanced molecular testing for patients and healthcare providers.

June 20, 2026

Genovation Health, Thermo Fisher Scientific, and XYGene Launch Strategic Co-Marketing Agreement to Expand Access to Integrated Genomic Solutions

Genovation Health has entered into a multi-year strategic co-marketing agreement with Thermo Fisher Scientific and XYGene to enhance the delivery and implementation of genomic diagnostics. The partnership aims to streamline clinical workflows by integrating genomic data directly into clinical decision support systems, addressing current challenges such as fragmented data and delayed results. This collaboration is significant for the precision medicine sector as it seeks to lower healthcare costs and improve patient outcomes through more efficient pharmacogenetic and predictive genomic testing.

June 20, 2026